Ertugliflozin
Green (Restricted)
Brand:
Steglatro®
Nice TA:
572
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
1.1 Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate
glycaemic control, only if:
-
a dipeptidyl peptidase 4 (DPP 4) inhibitor would otherwise be prescribed and
-
a sulfonylurea or pioglitazone is not appropriate
1.2 Ertugliflozin in a dual-therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
-
a sulfonylurea is contraindicated or not tolerated or
-
the person is at significant risk of hypoglycaemia or its consequences.
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: